Just a collection of some random cool stuff.
PS. Almost 99% of the contents here are not mine and I don't take credit for them, I reference and copy part of the interesting sections.
Hopes pinned on pre-emptive clinical trials after latest setbacks.
“The major conundrum in the field is: ‘are we just treating people too late?’.”
“We’ve had this concern for quite some time,” says Reiman, “that if these trials were negative we would see some major stakeholders and investors abandon amyloid-modifying treatments. We think that would be throwing the baby out with the bath water, and abandoning Alzheimer’s disease.”
Nature
489,
13–14
()
doi:10.1038/489013a
The bapineuzumab trials seem to have been more of an unqualified failure. This antibody drug targets the amyloid-β plaques, in hopes of awakening the immune system to clear them from the brain. But two trials in approximately 2,400 patients failed to show any benefit compared with a placebo, although this may have been because the drug was administered in lower doses than solanezumab, owing to its higher toxicity. Johnson & Johnson and its partner Pfizer, headquartered in New York city, say that they will vastly scale back development of bapineuzumab.
No comments:
Post a Comment